Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma

Histopathology

Volumn 58, Issue 5, 2011, Pages 679-692

  Stefanius, Karoliina ^a   Ylitalo, Laura ^a   Tuomisto, Anne ^a   Kuivila, Rami ^a   Kantola, Tiina ^a   Sirniö, Päivi ^a   Karttunen, Tuomo J ^a   Mäkinen, Markus J ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

BRAF; Colorectal cancer; DNA hypermethylation; HMLH1; KRAS; MGMT; Microsatellite instability; Serrated adenocarcinoma

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN MLH1;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER GENETICS; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MICROSATELLITE INSTABILITY; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PRIORITY JOURNAL; RECTUM CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 79951720589     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03821.x     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008; 58; 71-96.
2. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988; 319; 525-532.
3. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006; 38; 787-793.
4. Mäkinen MJ. Colorectal serrated adenocarcinoma. Histopathology 2007; 50; 131-150.
5. Tuppurainen K, Mäkinen JM, Junttila O et al. Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J. Pathol. 2005; 207; 285-294.
6. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50; 113-130.
7. O'Brien MJ. Hyperplastic and serrated polyps of the colorectum. Gastroenterol. Clin. North Am. 2007; 36; 947-968.
8. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989; 49; 4682-4689.
9. Kressner U, Bjorheim J, Westring S et al. Ki-ras mutations and prognosis in colorectal cancer. Eur. J. Cancer 1998; 34; 518-521.
10. Brink M, de Goeij AF, Weijenberg MP et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003; 24; 703-710.
11. Davies H, Bignell GR, Cox C. Mutations of the BRAF gene in human cancer. Nature 2002; 417; 949-954.
12. Kohonen-Corish MR, Cooper WA, Saab J, Thompson JF, Trent RJ, Millward MJ. Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. J. Invest. Dermatol. 2006; 126; 167-171.
13. Rosenberg DW, Yang S, Pleau DC et al. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res. 2007; 67; 3551-3554.
14. O'Brien MJ, Yang S, Huang CS, Shepher C, Cerda S, Farraye FA. The serrated polyp pathway to colorectal carcinoma. Diagn. Histopathol. 2008; 14; 78-93.
15. Spring KJ, Zhao ZZ, Karamatic R et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006; 131; 1400-1407.
16. Chan TL, Zhao W, Leung SY, Yuen ST, Cancer Genome Project. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res. 2003; 63; 4878-4881.
17. O'Brien MJ, Yang S, Mack C et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am. J. Surg. Pathol. 2006; 30; 1491-1501.
18. Mäkinen MJ, George SM, Jernvall P, Mäkelä J, Vihko P, Karttunen TJ. Colorectal carcinoma associated with serrated adenoma-prevalence, histological features, and prognosis. J. Pathol. 2001; 193; 286-294.
19. Berg KD, Griffin CA, Eshleman JR. Detection of microsatellite instability. In Killeen AA ed. Molecular pathology protocol. NJ, USA: Humana Press, 2001; 59.
20. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58; 5248-5257.
21. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 1996; 93; 9821-9826.
22. Zaidi NH, Pretlow TP, O'Riordan MA, Dumenco LL, Allay E, Gerson SL. Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Carcinogenesis 1995; 16; 451-456.
23. East JE, Saunders BP, Jass JR. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. Gastroenterol. Clin. North Am. 2008; 37; 25-46.
24. Young J, Simms LA, Biden KG et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am. J. Pathol. 2001; 159; 2107-2116.
25. Jass JR, Biden KG, Cummings MC et al. Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J. Clin. Pathol. 1999; 52; 455-460.
26. Sawyer EJ, Cerar A, Hanby AM et al. Molecular characteristics of serrated adenomas of the colorectum. Gut 2002; 51; 200-206.
27. Maltzman T, Knoll K, Martinez ME et al. Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. Gastroenterology 2001; 121; 302-309.
28. Barry EL, Baron JA, Grau MV, Wallace K, Haile RW. K-ras mutations in incident sporadic colorectal adenomas. Cancer 2006; 106; 1036-1040.
29. Bouzourene H, Gervaz P, Cerottini JP et al. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur. J. Cancer 2000; 36; 1008-1015.
30. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol. Biomarkers Prev. 2000; 9; 1193-1197.
31. Lin JK, Chang SC, Wang HS et al. Distinctive clinicopathological features of Ki-ras mutated colorectal cancers. J. Surg. Oncol. 2006; 94; 234-241.
32. Povey AC, Badawi AF, Cooper DP et al. DNA alkylation and repair in the large bowel: animal and human studies. J. Nutr. 2002; 132; 3518S-3521S.
33. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008; 26; 5705-5712.
34. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst. 2009; 101; 1308-1324.